Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of Cardiology’s 73rd Annual Scientific Congress in Atlanta, GA this week. The data was also released online, ahead of print, in a simultaneous manuscript in the...